Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Share-based Compensation (2016 - 2025)

Iradimed (IRMD) has disclosed Share-based Compensation for 13 consecutive years, with $666083.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 5.73% to $666083.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 19.05% increase, with the full-year FY2024 number at $2.5 million, up 15.44% from a year prior.
  • Share-based Compensation was $666083.0 for Q3 2025 at Iradimed, down from $730618.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $826064.0 in Q1 2025 to a low of $121003.0 in Q2 2022.
  • A 5-year average of $515141.5 and a median of $533748.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: tumbled 86.53% in 2021, then soared 369.79% in 2023.
  • Iradimed's Share-based Compensation stood at $391784.0 in 2021, then rose by 8.88% to $426555.0 in 2022, then increased by 29.19% to $551064.0 in 2023, then increased by 19.19% to $656835.0 in 2024, then rose by 1.41% to $666083.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Share-based Compensation are $666083.0 (Q3 2025), $730618.0 (Q2 2025), and $826064.0 (Q1 2025).